8-K: Phreesia Announces Solid Q4 and Fiscal Year 2025 Results, Maintains Optimistic 2026 Outlook

Phreesia reports a strong finish to fiscal 2025 with revenue growth, improved profitability, and maintains its fiscal 2026 outlook.

Summary

• Phreesia, Inc. announced its Q4 and full fiscal year 2025 results, showing revenue growth and improved profitability.
• Total revenue for Q4 2025 was $109.7 million, a 15% increase year-over-year.
• The average number of healthcare services clients (AHSCs) was 4,341, up 10% year-over-year.
• Total revenue per AHSC was $25,266, a 5% increase year-over-year.
• Net loss for the quarter was $6.4 million, a significant improvement from the $30.6 million loss in the same period last year.
• Adjusted EBITDA for the quarter was $16.4 million, compared to a negative $3.5 million in the prior year.
• For the full fiscal year 2025, revenue was $419.8 million, up 18% year-over-year.
• AHSCs for the year were 4,203, up 17% year-over-year.
• Net loss for the year was $58.5 million, a substantial improvement from the $136.9 million loss in fiscal 2024.
• Adjusted EBITDA for the year was $36.8 million, compared to a negative $35.4 million in the previous year.
• The company is maintaining its fiscal 2026 revenue outlook in the range of $472 million to $482 million.
• Adjusted EBITDA for fiscal 2026 is expected to be in the range of $78 million to $88 million.
• Phreesia anticipates reaching approximately 4,500 AHSCs in fiscal 2026 and expects total revenue per AHSC to increase from fiscal 2025.
• The company had $84.2 million in cash and cash equivalents as of January 31, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and maintained guidance for the future. While there are some negative aspects, the overall tone is optimistic and suggests a healthy financial trajectory for the company.

Positives

• Revenue is up 15% year-over-year for Q4 2025, reaching $109.7 million.
• Adjusted EBITDA improved significantly, reaching $16.4 million in Q4 2025 compared to negative $3.5 million in the same period last year.
• Net loss decreased substantially, from $30.6 million in Q4 2024 to $6.4 million in Q4 2025.
• Full fiscal year 2025 revenue increased by 18% year-over-year to $419.8 million.
• Full fiscal year 2025 Adjusted EBITDA improved to $36.8 million from negative $35.4 million in the previous year.
• Net cash provided by operating activities was $16.3 million in Q4 2025, compared to net cash used in operating activities of $3.1 million in the same period last year.
• Free cash flow was $9.2 million in Q4 2025, compared to negative $10.9 million in the same period last year.
• The company is maintaining its revenue and Adjusted EBITDA outlook for fiscal 2026.
• Appointment Readiness product pilot phase showed that 82% of patients found the information helpful.
• Patient Bill Pay implementation at an orthopedic group resulted in a 35% increase in payments collected outside the time of service and a 331% increase in overall transactions.

Negatives

• Healthcare services revenue per AHSC was $17,616 in Q4 2025, only up 1% year-over-year.
• Healthcare services revenue per AHSC was $70,961 in fiscal 2025, down 2% year-over-year.
• Cash and cash equivalents decreased from $87.5 million as of January 31, 2024, to $84.2 million as of January 31, 2025.
• The wind-down of a clearinghouse client relationship negatively impacted year-over-year payment processing fees revenue growth and total revenue growth by 7% and 1%, respectively.

Risks

• The company's ability to effectively manage growth and meet growth objectives.
• The competitive environment in which the company operates.
• The company's ability to comply with the covenants in its credit agreement with Capital One.
• Changes in market conditions and receptivity to the company's products and services.
• The company's ability to develop and release new products and services and successful enhancements, features and modifications to its existing products and services.
• The company's ability to maintain the security and availability of its platform.
• The impact of cyberattacks, security incidents or breaches impacting the company's business.
• Changes in laws and regulations applicable to the company's business model.
• The company's ability to make accurate predictions about its industry and addressable market.
• The company's ability to attract, retain and cross-sell to healthcare services clients.
• The company's ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent.
• The company's ability to realize the intended benefits of its acquisitions and partnerships.
• Difficulties in integrating the company's acquisitions and investments.
• Other general market, political, economic and business conditions, including the results of the 2024 U.S. presidential and congressional elections and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere.

Future Outlook

Phreesia maintains its revenue outlook for fiscal 2026, expecting revenue to be in the range of $472 million to $482 million. Adjusted EBITDA is expected to be in the range of $78 million to $88 million. The company anticipates reaching approximately 4,500 AHSCs and expects total revenue per AHSC to increase from fiscal 2025.

Management Comments

• 'We are pleased with our solid finish to fiscal 2025 and I am excited about the new products we have introduced over the past several quarters that improve medication adherence and the overall patient and provider experience,' said CEO and Co-Founder Chaim Indig.

Industry Context

Phreesia operates in the healthcare technology sector, providing patient activation and payment solutions. The company's growth is driven by the increasing adoption of digital health solutions and the shift towards patient-centric care. The company's solutions address key challenges in healthcare, such as patient engagement, revenue cycle management, and access to care.

Comparison to Industry Standards

• Phreesia's revenue growth of 18% for fiscal year 2025 is competitive within the healthcare technology sector.
• Companies like Veeva Systems and athenahealth are comparible companies in the healthcare technology sector.
• Phreesia's focus on Adjusted EBITDA and free cash flow aligns with industry standards for measuring profitability and financial health.
• The company's AHSC growth and total revenue per AHSC metrics are key indicators of its ability to expand its customer base and generate revenue from existing clients.

Stakeholder Impact

• Shareholders: The positive financial results and maintained outlook are likely to be viewed favorably by shareholders.
• Employees: The company's growth and profitability may lead to increased job security and potential for career advancement.
• Customers: The company's focus on improving patient experience and healthcare outcomes is likely to benefit customers.
• Suppliers: The company's growth may lead to increased demand for suppliers' products and services.
• Creditors: The company's strong financial position reduces the risk for creditors.

Next Steps

• The company will hold a conference call on March 12, 2025, to review the fiscal fourth quarter and fiscal 2025 financial results.
• The company will file its Annual Report on Form 10-K for the fiscal year ended January 31, 2025, with the SEC.

Key Dates